Galapagos NV

Last updated: 01.02.2019

company_picture

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Their pipeline comprises several studies, pre-clinical and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.

The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.

Interviews

Related

We use cookies to ensure that we give you the best experience on our site. For more info click here